P
Paul A. Pham
Researcher at Johns Hopkins University
Publications - 11
Citations - 485
Paul A. Pham is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: Efavirenz & Population. The author has an hindex of 7, co-authored 11 publications receiving 429 citations.
Papers
More filters
Journal ArticleDOI
Clinical Practice Guideline for the Management of Chronic Kidney Disease in Patients Infected With HIV: 2014 Update by the HIV Medicine Association of the Infectious Diseases Society of America
Gregory M. Lucas,Michael W. Ross,Peter G. Stock,Michael G. Shlipak,Christina M. Wyatt,Samir K. Gupta,Mohamed G. Atta,Kara Wools-Kaloustian,Paul A. Pham,Leslie A. Bruggeman,Jeffrey L. Lennox,Patricio E. Ray,Robert C. Kalayjian +12 more
TL;DR: IDSA considers adherence to these guidelines to be voluntary, with the ultimate determination regarding their application to be made by the physician in the light of each patient's individual circumstances.
Journal ArticleDOI
Antiretroviral therapy adherence and drug-drug interactions in the aging HIV population
TL;DR: It is estimated that by 2015 more than half of all HIV-infected individuals in the United States will be 50 years of age or older, and well designed ART adherence interventions and DDI studies are needed in the elderly HIV population.
Journal ArticleDOI
Provisional Guidance on the Use of Hepatitis C Virus Protease Inhibitors for Treatment of Hepatitis C in HIV-Infected Persons
David L. Thomas,John G. Bartlett,Marion G. Peters,Kenneth E. Sherman,Mark S. Sulkowski,Paul A. Pham +5 more
TL;DR: Provisional guidance on the use of HCV PIs in HIV-infected persons is provided.
Journal ArticleDOI
Severe Prolonged Sedation Associated with Coadministration of Protease Inhibitors and Intravenous Midazolam During Bronchoscopy
TL;DR: Patients who received intravenous midazolam during an inpatient bronchoscopy procedure were more likely to experience severe prolonged sedation if they were taking antiretroviral therapy that included a protease inhibitor versus those who were not taking any antireteviral therapy.